Bimekizumab for the treatment of psoriatic arthritis

Expert Rev Clin Immunol. 2023 Nov 1. doi: 10.1080/1744666X.2023.2277266. Online ahead of print.ABSTRACTINTRODUCTION: Interleukin (IL)-17A and IL-17F have overlapping roles in pro-inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease. Bimekizumab is the first human monoclonal antibody to selectively inhibit IL-17F in addition to IL17A. Bimekizumab has been studied in several phase II/III trials and has been approved for the treatment of patients with psoriatic arthritis (PsA) in the EU and UK.AREAS COVERED: A literature search identified clinical trials examining the efficacy and safety of bimekizumab for PsA, which were critically appraised.EXPERT OPINION: Clinical trials of bimekizumab in PsA have demonstrated rapid and sustained treatment responses and depth of response across the multiple disease domains. High levels of efficacy were sustained to 152 weeks in phase IIb trials, and to 52 weeks in phase III trials. Bimekizumab was generally well tolerated. As expected, due to the role of IL17 in the immune response to fungal pathogens, there was an increase in mildtomoderate, localized fungal infections with bimekizumab treatment, very few of which led to discontinuation. Studies over longer time periods, with relevant comparators from the IL-17A inhibitor class, and real-world data will be important to further define the role of bimekizumab among currently available treatments for PsA.PMID:37909894 | DOI:10.1080/1744666X.2023.2277266
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research